“Active Trust” is at the core of our company and is fundamental to our decision-making process. We have each other’s back, prioritizing transparency and mutual respect within our team. Learn more: https://lnkd.in/etdzEAVY
Sionna Therapeutics
Biotechnology
Boston, MA 3,962 followers
Dedicated to delivering therapies that could be transformational for people living with cystic fibrosis.
About us
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
- Website
-
https://www.sionnatx.com/
External link for Sionna Therapeutics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- life sciences, biotechnology, pharmaceuticals, cystic fibrosis, protein function, genetics, genetic mutation, genetic disease, clinical research, clinical study, research, small molecule, molecular engineering, chemistry, patient advocacy, drug development, clinical development, lung, orphan disease, and rare disease
Locations
-
Primary
Boston, MA, US
Employees at Sionna Therapeutics
Updates
-
#ICYMI Our President & CEO, Mike Cloonan, discussed our recently closed licensing deal with AbbVie in LifeSciVC’s recent "From The Trenches" blog organized by Bruce Booth of Atlas Venture. Read the full article here: https://lnkd.in/ecMGrUKS
-
Individuals with #cysticfibrosis (CF) inherit genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, causing the #CFTR protein to malfunction. This results in the production of thick, sticky mucus, which can lead to recurrent infections and loss of function in the affected organs. Learn more from the American Lung Association at https://lnkd.in/ezJZXab9
-
As we wrap up the summer with our Project Onramp interns, Robel Birega and Danish Abbasi, we want to reflect on their time with us and express our gratitude for their hard work and enthusiasm. Their contributions have been impactful, and we’re excited about the progress they’ve made throughout their #internship. Thank you, Robel and Danish, for a great summer. We wish you all the best in your future endeavors!
-
This week our interns from Project Onramp, Robel Birega and Danish Abbasi, showcased the impactful work they accomplished this summer at Sionna. As we say our goodbyes, we are thankful to Life Science Cares Boston for providing us with the opportunity to collaborate with such motivated individuals. We can’t wait to see what they do next!
-
We are pleased to announce the initiation of two Phase 1 clinical trials to evaluate the safety, tolerability and pharmacokinetics of our product candidates from our next generation series of highly potent #NBD1 stabilizers. With this milestone, we are continuing to execute towards our goal of achieving improved clinical benefits for people living with cystic fibrosis (#CF). See our press release for details: https://lnkd.in/everBqD7
-
For William, who lives with CF, the Cystic Fibrosis Foundation’s #GreatStrides fundraiser offered a sense of community and normalcy during his childhood. In this article, he shares his experience taking part in the walkathon and highlights the importance of advocacy in progressing #CF research: https://lnkd.in/eZbqYDWv As we strive to improve outcomes for the CF community, we're proud to have participated in the Great Strides initiative for the past two years. Together, we are helping to raise awareness and fund research for #CF one step at a time!
-
Following the execution of our license agreement with AbbVie to develop and commercialize multiple clinical-stage compounds, see our expanded #cysticfibrosis (CF) pipeline here: https://lnkd.in/eF43fsMj
-
#ICYMI We announced a license agreement for multiple clinical-stage compounds from AbbVie to expand and accelerate our pipeline of complementary modulators to combine with our novel NBD1 portfolio in #cysticfibrosis (CF). We believe we are well-positioned to advance our dual combination development path toward our goal of providing more efficacious #CF treatment options. Read our press release for details: https://lnkd.in/eTJgBmbr
-
Since our start in 2019, we've remained committed to fostering strong connections among our team members and within the cystic fibrosis community. From recognizing our team’s achievements to supporting the Cystic Fibrosis Foundation's Great Strides Walk, and most recently, engaging in team-building activities on Cathleen Stone Island, we continually show that our dedication to collaboration goes beyond the workplace. Check out the ways we've strengthened our bonds and come together as a team in 2024!